Cover Image
市場調查報告書

室膜瘤治療藥:開發中產品分析

Ependymoma - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 484623
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
Back to Top
室膜瘤治療藥:開發中產品分析 Ependymoma - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 131 Pages
簡介

本報告提供室膜瘤治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中治療藥,治療藥評估,暫停中·中止的計劃等相關資訊。

簡介

  • 調查範圍

室膜瘤 - 概要

室膜瘤 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 企業開發中的產品

室膜瘤 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

室膜瘤的開發治療藥的企業

室膜瘤 - 藥物簡介

室膜瘤 - 暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9698IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ependymoma - Pipeline Review, H2 2017, provides an overview of the Ependymoma (Oncology) pipeline landscape.

Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebellum. The tumor often blocks the flow of the cerebral spinal fluid (CSF), causing increased intracranial pressure. Ependymomas are often slow growing tumours, and any signs and symptoms usually develop slowly over many months. The treatment for an ependymoma depends on a number of things, including your general health, the size and position of the tumour, and whether it has spread to other parts of the brain or spinal cord.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ependymoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ependymoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ependymoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ependymoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 5 and 5 respectively.

Ependymoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ependymoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ependymoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ependymoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ependymoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ependymoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ependymoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ependymoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ependymoma - Overview
    • Ependymoma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Ependymoma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Ependymoma - Companies Involved in Therapeutics Development
    • Advantagene Inc
    • Amgen Inc
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Cavion LLC
    • Celgene Corp
    • Eli Lilly and Company
    • Millennium Pharmaceuticals Inc
    • NewLink Genetics Corp
    • Ono Pharmaceutical Co Ltd
  • Ependymoma - Drug Profiles
    • abemaciclib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • afatinib dimaleate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-207 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GliAtak - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • indoximod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ipilimumab + nivolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mibefradil dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • R&D Progress
    • pomalidomide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ependymoma - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Ependymoma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Ependymoma - Pipeline by Advantagene Inc, H2 2017
  • Ependymoma - Pipeline by Amgen Inc, H2 2017
  • Ependymoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Ependymoma - Pipeline by Bristol-Myers Squibb Company, H2 2017
  • Ependymoma - Pipeline by Cavion LLC, H2 2017
  • Ependymoma - Pipeline by Celgene Corp, H2 2017
  • Ependymoma - Pipeline by Eli Lilly and Company, H2 2017
  • Ependymoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • Ependymoma - Pipeline by NewLink Genetics Corp, H2 2017
  • Ependymoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
  • Ependymoma - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Ependymoma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top